In the U.S.

Radiochemistry & Molecular Imaging Probes

Serge K. Lyashchenko

Director

The Radiochemistry and Molecular Imaging Probes (RMIP) Core functions at the intersection of the Cancer Center’s laboratory research and clinical molecular imaging initiatives—including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology, and engineering, and is one of the largest manufacturing units at MSK in terms of the number of clinical and research products produced. The RMIP Core was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core consists of 4 major elements working closely together to provide the following services: the Cyclotron Radionuclide Production Section, the Radiolabeling Section, the Development and Clinical Translation Section, and the Hyperpolarized Magnetic Resonance Section. MSK and the RMIP Core have an outstanding reputation for supporting clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 25 years, the RMIP Core has produced over 60 radiopharmaceuticals and molecular imaging agents for research clinical trials (imaging and therapy) in humans including radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics.

Serge Lyashchenko in the cyclotron facility — Radiopharmacist Serge Lyashchenko preparing a reagent in the cyclotron facility.

RMIP Core group — Radiochemistry and Molecular Imaging Probe Core

Featured News

In the Clinic

How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise

Friday, June 27, 2014

The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.